Business
Curis Provides First Quarter 2026 Business Update
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business update and financial results for the quarter ended March 31, 2026.
About this update from Curis, Inc.
[{"type":"text","content":"Management to host conference call today at 4:30 p.m. ET","length":56,"tagName":"p","attribs":{}},{"type":"text","content":"LEXINGTON, Mass., May 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business update and financial results for the quarter ended March 31, 2026.","length":308,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Curis, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Curis, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":207,"url":"https://media.zenfs.com/en/prnewswire.com/88fd3af4c52bfd02eedb20e78872ec1a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bs_Ynz1IdxzlIjT8sYZeig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM2NTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/88fd3af4c52bfd02eedb20e78872ec1a","width":400,"height":207},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ytwMPiOO69eKEMdg7BSQQg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMzMTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/88fd3af4c52bfd02eedb20e78872ec1a","width":400,"height":207}},"href":"https://mma.prnewswire.com/media/607886/Curis_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Operational Highlights","length":22,"tagName":"p"},{"type":"text","content":"TakeAim Lymphoma","length":16,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Emavusertib is currently undergoing testing in combination with the Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib in the TakeAim Lymphoma Phase 1/2 open-label, single arm expansion trial in patients with Relapsed or Refractory (R/R) Primary CNS Lymphoma (PCNSL) (CA-4948-101, NCT03328078). Patient enrollment in this study is currently ongoing. As a result of discussions with FDA and EMA, the ongoing phase 1/2 study is intended to support filings for accelerated approval of emavusertib in PCNSL in the US and Europe. Emavusertib has been granted orphan drug designation by both FDA and EMA in PCNSL.","length":612,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":612,"olType":false},{"type":"text","content":"TakeAim CLL ","length":11,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Emavusertib is ...